AAA - Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the treatment of abdominal aortic aneurysms.
Learn more
ALIDIAL - A phase III trial to evaluate the efficacy and safety of biweekly alirocumab in patients on a stable dialysis regimen.
Learn more
CLEAR - A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with or at high risk for cardiovascular disease who are statin intolerant.
Learn more
DREAM - A double-blind, randomized, sham-procedure-controlled, parallel-group efficacy and safety study of Allogeneic Mesenchymal Precursor Cells (rexlemesrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology.
Learn more
Emperor Preserved - A phase III randomized, double-blind trial to evaluate the efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic heart failure with preserved ejection fraction (HFpEF).
Learn more
GREAT – A global registry for endovascular aortic treatment outcomes evaluation.
Learn more
GUARD –A multicenter, prospective, parallel-group, double-blind, randomized, placebo-controlled, phase II study of BB3 to assess the safety and efficacy of BB3 in patients developing acute kidney injury after cardiac surgery.
Learn more
HUMANITY – An assessment of humacyte’s human acellular vessel in patients needing renal replacement therapy: A comparison with ePTFE grafts as conduits for hemodialysis.
Learn more
On-X – A longitudinal, randomized study comparing the On-X valve on low dose anticoagulation to concomitant control groups of On-X valves receiving standard Coumadin/aspirin therapy.
Learn more
PARADISE – A multi-center, randomized, double-blind, active-controlled, parallel-group Phase III study to evaluate the efficacy and safety of LCZ696 (Entresto) compared to Ramipril on morbidity and mortality in high risk patients following an acute myocardial infection.
Learn more
Perspective - A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 (Entresto™) compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.
Learn more
QUARK 309 – A randomized, double-blind, placebo controlled, Phase III study to evaluate the efficacy and safety of QPI-1002 for the prevention of major adverse kidney events in subjects at high risk for acute kidney injury (AKI) following cardiac surgery.
Learn more
SPYRAL PIVOTAL – SPYRAL HTN-OFF MED - A multi-center, prospective, single blinded, 1:1 randomized, sham-procedure controlled global clinical study of renal denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension in the absence of antihypertensive medication.
Learn more
SPYRAL HTN-ON MED - A multi-center, prospective, single blinded, 2:1 (treatment to control) randomized, sham-procedure controlled global clinical study of renal denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy.
Learn more
